BEUDAMED
    FDA Adverse Event Malfunction Summary report: N

    ECLIPSE2L BALLOON CATHETER

    MDR report key: 14048747 · Received April 7, 2022

    Report

    Report Number
    3014162263-2022-00011
    Event Type
    Malfunction
    Date Received
    April 7, 2022
    Date of Event
    February 28, 2022
    Report Date
    March 28, 2022
    Manufacturer
    BALT USA
    Product Code
    MJN
    UDI-DI
    00818053022968
    PMA / PMN Number
    K183045
    Product Problem
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    TX, US
    Reporter Occupation
    PHYSICIAN
    Health Professional
    Yes

    Narratives

    Additional Manufacturer Narrative · 0

    BALT USA'S REFERENCE NUMBER: (B)(4). THE ANALYSIS OF THE COMPLAINT WAS PERFORMED BY SUPPLIER BALT EXTRUSION FOR DEEPER INVESTIGATION, SUMMARY PROVIDED AS FOLLOWS: THE AFFECTED CATHETER ECLIPSE2L HAS NOT BEEN RETURNED TO BALT EXTRUSION SAS FOR INSPECTION. AS A RESULT, THE ANALYSIS OF THE REPORTED EVENT WAS LIMITED. THE REVIEW WAS BASED ON THE INCIDENT DESCRIPTION, THE DEVICE HISTORY RECORDS, AND THE DATA GATHERED DURING OUR POST-MARKETING SURVEILLANCE PROGRAM FOR SUCH FAILURES. THE LOT HISTORY RECORDS (LHRS) REVIEW FOR THIS SPECIFIC BATCH NUMBER DID NOT HIGHLIGHT ANY ANOMALY DURING THE MANUFACTURING PROCESS. SEVERAL TESTS WERE PERFORMED DURING THE MANUFACTURING PROCESS: THE BRAID, THE TUBE, AND THE BALLOON ARE 100% CONTROLLED WITH A VISUAL INSPECTION ; A TIGHTNESS TEST OF THE BALLOON IS ALSO PERFORMED ON EVERY UNIT ; THE INTEGRITY OF THE MICRO-CATHETERS IS 100% CONTROLLED ; THE HYDROPHILIC COATING APPEARANCE AND CLEANLINESS ARE 100% CONTROLLED ; A SLIDING TEST IS ALSO PERFORMED ON A SAMPLE OF MICROCATHETERS ; THE RINGS ARE 100% CONTROLLED. THERE IS NO OTHER COMPLAINT REGISTERED ON THIS LOT NUMBER TO DATE. THE INCIDENT DESCRIPTION MENTIONED THAT AFTER THE INJECTION OF THE EMBOLIC AGENT, THE ECLIPSE2L REVEALED BEING ENTRAPPED INTO THIS ("[...] SENSITIVE FUSIFORM BASILAR ANEURYSM THAT WAS SLOWLY SACRIFICING WITH A LIQUID EMBOLIC. ONCE THE EMBOLIZATION WAS COMPLETE, HE LIGHTLY PULLED ON THE ECLIPSE WITHOUT SUCCESSFUL REMOVAL"). BY CORRELATING THIS INFORMATION WITH OUR POST-MARKETING SURVEILLANCE PROGRAM, SUCH BLOCKAGES ARE GENERALLY CAUSED BY THE EMBOLIC AGENT REFLUX BEYOND THE CATHETER'S DISTAL EXTREMITY DURING THE INJECTION. SO, THIS INCIDENT TYPE IS UNLIKELY LINKED TO THE DEVICE ITSELF. IN CONCLUSION, THE INCIDENT REPORTED (CATHETER TRAPPING) CANNOT BE LINKED TO A POTENTIAL TECHNICAL FAILURE OF THE BALLOON CATHETER ECLIPSE2L. MANUFACTURING RECORDS COMPLIED WITH SPECIFICATIONS, AND THE PRODUCT WAS NOT AVAILABLE FOR INSPECTION. THE TREND OF THIS FAILURE MODE WILL CONTINUE TO BE MONITORED AS PART OF OUR POST-MARKETING SURVEILLANCE PROGRAM. REVIEW OF THE LOT HISTORY RECORDS DID NOT REVEAL ANY IN-PROCESS OR LOT-SPECIFIC ISSUE THAT COULD ACCOUNT FOR THE OBSERVATION. NO ADDITIONAL COMPLAINTS AGAINST LOT NUMBER F211200089 HAS BEEN MADE FOR THE SAME ISSUE. COMPREHENSIVE ANALYSIS OF THIS FAILURE MODE HAS REMAINED SUBJECT TO MONITORING FOR ANY UNACCEPTABLE INCREASE IN TREND. THE SUBMISSION OF THIS REPORT OR RELATED INFORMATION TO THE FDA, AND ITS RELEASE BY FDA, DOES NOT REFLECT A CONCLUSION BY THE PARTY SUBMITTING THIS REPORT OF THE FDA THAT THE REPORT OR RELATED INFORMATION IS AN ADMISSION THAT THE MANUFACTURER, THEIR EMPLOYEES, OR THE DEVICE CAUSED OR CONTRIBUTED TO THE REPORTABLE EVENT.

    Description of Event or Problem · 0

    IT WAS REPORTED THAT: "THE ECLIPSE BALLOON BECAME ENTRAPPED AFTER USE AND THE PHYSICIAN HAD TO CUT IT AT THE GROIN ACCESS SITE." 09MAR2022 - ADDITIONAL INFORMATION RECEIVED FROM THE ISSUER: "COULD YOU PROVIDE ADDITIONAL DETAILS ON THE INCIDENT? EVERYTHING I KNOW ABOUT THE PROCEDURE I HAVE DISCLOSED BUT THE PHYSICIAN COULD BE CONTACTED FOR ADDITIONAL INFORMATION. CAN YOU CONFIRM THAT NO HARM OCCURRED TO THE PATIENT? ACCORDING TO THE PHYSICIAN THE PATIENT WAS NOT HARMED. WAS THE PRODUCT ENTRAPPED DUE TO THE LIQUID EMBOLIC? YES, THE PHYSICIAN WAS USING ONYX APPROXIMATELY WHERE WAS THE CATHETER CUT? ACCORDING TO THE PHYSICIAN IT WAS CUT AT THE FEMORAL ARTERY ACCESS SITE." 23MAR2022 - ADDITIONAL INFORMATION FROM ISSUER: COULD YOU PLEASE TELL US HOW THE CATHETER HAD BEEN ENTRAPPED? WAS IT FOLLOWING A REFLUX OF EMBOLIC AGENT? THE PHYSICIAN COMMUNICATED TO ME THAT THE PATIENT HAD A SENSITIVE FUSIFORM BASILAR ANEURYSM THAT WAS SLOWLY SACRIFICING WITH A LIQUID EMBOLIC. ONE THE EMBOLIZATION WAS COMPLETE HE LIGHTLY PULLED ON THE ECLIPSE WITHOUT SUCCESSFUL REMOVAL BUT BECAUSE OF THE NATURE OF THE DISEASE HE DID NOT WANT TO PULL EXCESSIVELY. THEREFORE HE CUT THE CATHETER AT THE GROIN ACCESS SITE LEAVING IN THE ENTIRE DEVICE. COULD YOU PLEASE GIVE US INFORMATION ABOUT THE HEALTH STATUS OF THE PATIENT? THE PATIENT IS STABLE AND NOT EXPERIENCING ANY ADVERSE EVENTS FROM THE ECLIPSE. COULD YOU PLEASE TELL US IF THE TOTALITY OF THE ECLYSPE2L COULD BE REMOVED FROM THE PATIENT (INCLUDING THE DISTAL PART ENTRAPPED)?

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    2491997 ECLIPSE2L BALLOON CATHETER ECLIPSE2L MJN BALT USA ECL2L6X12 F211200089 00818053022968

    Patients

    Seq Age Sex Outcome Treatment
    1 Unknown Required Intervention